MTOR and breast carcinoma: Diosgenin arrested the cell cycle at sub-G1 phase, suppressed FAS expression, and inhibited mammalian target of rapamycin (mTOR) phosphorylation in HER2 overexpressing human AU565 breast cancer cells, inhibiting cell proliferation [78].